

Kathryn H. Ruemmler
kathryn.ruemmler@lw.com
(202) 637 2179

555 Eleventh Street, N.W., Suite 1000
Washington, D.C. 20004-1304
Tel: +1.202.637.2200 Fax: +1.202.637.2201
www.lw.com

LATHAM & WATKINS LLP

FIRM / AFFILIATE OFFICES

Barcelona	Moscow
Beijing	Munich
Boston	New York
Brussels	Orange County
Century City	Paris
Chicago	Riyadh
Dubai	Rome
Düsseldorf	San Diego
Frankfurt	San Francisco
Hamburg	Seoul
Hong Kong	Shanghai
Houston	Silicon Valley
London	Singapore
Los Angeles	Tokyo
Madrid	Washington, D.C.
Milan	

November 18, 2016

VIA E-MAIL


The Honorable Charles E. Grassley
Chairman
Committee on the Judiciary
United States Senate
224 Dirksen Senate Office Building
Washington, DC 20510

Dear Chairman Grassley:

On behalf of my client, Mylan N.V. ("Mylan" or the "Company"), I am writing to respond to your November 1, 2016 invitation to Mylan to testify before the Senate Committee on the Judiciary (the "Committee") on November 30, 2016 at a hearing entitled "Oversight of the EpiPen Crisis and Settlement: Where is the Federal Government in Looking out for Taxpayers and Patients?"

From the stated title of the hearing, we understand that the intended focus of the hearing will be on the Committee's oversight of government agencies as it relates to a pending matter. Further, we understand that representatives of those government agencies have confirmed to the Committee that they are not able to send a witness to testify or provide further information about this matter while it is pending. Given the stated focus of the proposed hearing, the fact that it involves a pending matter, and that the government agencies in question will not be able to send a witness to testify or provide further information, Mylan respectfully declines the invitation to testify.

Sincerely,



Kathryn H. Ruemmler of
LATHAM & WATKINS LLP

cc: The Honorable Patrick J. Leahy
Ranking Member